• Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, Garcia-Gomez M, Leceta J, Gomariz RP 2005 cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm. Bowel Dis. 11: 674-684. *

• Abonia JP, Austen KF, Rollins BJ, Joshi SK, Flavell RA, Kuziel WA, Koni PA, Gurish MF 2005 Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2. Blood 105: 4308-4313. *

• Adarichev VA, Vermes C, Hanyecz A, Ludanyi K, Tunyogi-Csapo M, Finnegan A, Mikecz K, Glant TT 2006 Antigen-induced differential gene expression in lymphocytes and gene expression profile in synovium prior to the onset of arthritis. Autoimmunity 39: 663-673.

• Aggarwal A, Agarwal S, Misra R 2007 Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5(+) and CXCR3(+) CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA). Clin. Exp. Immunol. 148: 515-519. *

• Aguilar F, Nunez-Roldan A, Torres B, Wichmann I, Sanchez-Roman J, Gonzalez-Escribano MF 2003 Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. J. Rheumatol. 30: 1770-1774.

• Ahlenstiel G, Woitas RP, Rockstroh J, Spengler U 2004 CC-chemokine receptor 5 (CCR5) in hepatitis C - at the crossroads of the antiviral immune response? J. Antimicrob. Chemother. 53: 895-898. *

• Ahn SH, Kim DY, Chang HY, Hong SP, Shin JS, Kim YS, Kim H, Kim JK, Paik YH, Lee KS, Chon CY, Moon YM, Han KH 2006 Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. J. Med. Virol. 78: 1564-1571. *

• Ajuebor MN, Aspinall AI, Zhou F, Le T, Yang Y, Urbanski SJ, Sidobre S, Kronenberg M, Hogaboam CM, Swain MG 2005 Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells. J. Immunol. 174: 8027-8037. *

• Ajuebor MN, Carey JA, Swain MG 2006 CCR5 in T cell-mediated liver diseases: what's going on? J. Immunol. 177: 2039-2045. *

• Ajuebor MN, Wondimu Z, Hogaboam CM, Le T, Proudfoot AE, Swain MG 2007 CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am. J. Pathol. 170: 1975-1988. *

• Akashi S, Sho M, Kashizuka H, Hamada K, Ikeda N, Kuzumoto Y, Tsurui Y, Nomi T, Mizuno T, Kanehiro H, Hisanaga M, Ko S, Nakajima Y 2005 A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 80: 378-384.

• Al-Saleh J, el-Eissawy S 2006 The role of T helper cell subsets in pathogenesis of systemic lupus erythematosus and their relation to disease activity. Egypt J. Immunol. 13: 41-48.

• Alfano M, Crotti A, Vicenzi E, Poli G 2008 New players in cytokine control of HIV infection. Curr. HIV/AIDS Rep. 5: 27-32.

• Algood HM, Flynn JL 2004 CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. J. Immunol. 173: 3287-3296. *

• Andres PG, Beck PL, Mizoguchi E, Mizoguchi A, Bhan AK, Dawson T, Kuziel WA, Maeda N, MacDermott RP, Podolsky DK, Reinecker HC 2000 Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J. Immunol. 164: 6303-6312. *

• Ansari AW, Heiken H, Moenkemeyer M, Schmidt RE 2007 Dichotomous effects of C-C chemokines in HIV-1 pathogenesis. Immunol. Lett. 110: 1-5.

• Apostolakis S, Baritaki S, Krambovitis E, Spandidos DA 2005 Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population. J. Clin. Virol. 34: 310-314.

• Aranami T, Yamamura T 2008 Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Int. 57: 115-120. *

• Ariel A, Fredman G, Sun YP, Kantarci A, Van Dyke TE, Luster AD, Serhan CN 2006 Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat. Immunol. 7: 1209-1216. *

• Bagnoli S, Putignano AL, Melean G, Baglioni S, Sestini R, Milla M, d'Albasio G, Genuardi M, Pacini F, Trallori G, Papi L 2004 Susceptibility to refractory ulcerative colitis is associated with polymorphism in the hMLH1 mismatch repair gene. Inflamm. Bowel Dis. 10: 705-708. *

• Balistreri CR, Grimaldi MP, Vasto S, Listi F, Chiappelli M, Licastro F, Lio D, Caruso C, Candore G 2006 Association between the polymorphism of CCR5 and Alzheimer's disease: results of a study performed on male and female patients from northern Italy. Ann. N. Y. Acad. Sci. 1089: 454-461. *

• Bamshad MJ, Mummidi S, Gonzalez E, Ahuja SS, Dunn DM, Watkins WS, Wooding S, Stone AC, Jorde LB, Weiss RB, Ahuja SK 2002 A strong signature of balancing selection in the 5' cis-regulatory region of CCR5. Proc. Natl. Acad. Sci. U.S.A. 99: 10539-10544. *

• Baragiotta A, Floreani A, Agarwal K, Venturi C, Craggs A, Jones DEJ, Donaldson PT, Bassendine MF 2004 Chemokine receptor 5 and primary biliary cirrhosis: a two-centre genetic association study. Liver Int. 24: 646-650. *

• Barcellos LF, Schito AM, Rimmler JB, Vittinghoff E, Shih A, Lincoln R, Callier S, Elkins MK, Goodkin DE, Haines JL, Pericak-Vance MA, Hauser SL, Oksenberg JR 2000 CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 51: 281-288.

• Batra J, Sharma M, Chatterjee R, Sharma S, Mabalirajan U, Ghosh B 2005 CCR5 Delta32 deletion and atopic asthma in India. Thorax 60: 85. *

• Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ 1997 The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum. Immunol. 58: 52-59.

• Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ 2004 Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020. *

• Bhattacharyya Majumdar S, Dey R, Majumder N, Bhattacharjee S, Majumdar S 2008 A novel approach to regulate experimental visceral leishmaniasis in murine macrophages using CCR5 siRNA. Scand. J. Immunol. 67: 345-353.

• Bian GX, Miao H, Qiu L, Cao DM, Guo BY 2005 Profiling of differentially expressed chemotactic-related genes in MCP-1 treated macrophage cell line using human cDNA arrays. World J. Gastroenterol. 11: 2508-2512. *

• Bisset LR, Schmid-Grendelmeier P 2005 Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr. Opin. Pulm. Med. 11: 35-42.

• Blanpain C, Libert F, Vassart G, Parmentier M 2002 CCR5 and HIV infection. Receptors Channels 8: 19-31.

• Boasso A, Hardy AW, Landay AL, Martinson JL, Anderson SA, Dolan MJ, Clerici M, Shearer GM 2008 PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin. Immunol. Jul 21 [Epub ahead of print]. *

• Bogner J, Lutz B, Klein H, Pollerer C, Troendle U, Goebel F 2004 Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV Med. 5: 264-272.

• Bogunia-Kubik K, Jaskula E, Lange A 2007 The presence of functional CCR5 and EBV reactivation after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 40: 145-150.

• Borgmann S, Haubitz M 2004 Genetic impact of pathogenesis and prognosis of ANCA-associated vasculitides. Clin. Exp. Rheumatol. 22 (6 Suppl. 36): S79-S86.

• Bovolenta C, Biswas P, Vicenzi E, Poli G 1998 Double doors and gatekeepers: HIV co-receptors and chemokines. Drug News Perspect. 11: 620-624.

• Brabcova I, Petrasek J, Hribova P, Hyklova K, Bartosova K, Lacha J, Viklicky O 2007 Genetic variability of major inflammatory mediators has no impact on the outcome of kidney transplantation. Transplantation 84: 1037-1044.

• Brajao de Oliveira K, Vissoci Reiche EM, Kaminami Morimoto H, Pelegrinelli Fungaro MH, Estevao D, Pontello R, Franco Nasser T, Watanabe MA 2007 Analysis of the CC chemokine receptor 5 delta32 polymorphism in a Brazilian population with cutaneous leishmaniasis. J. Cutan. Pathol. 34: 27-32. *

• Bream JH, Young HA, Rice N, Martin MP, Smith MW, Carrington M, O'Brien SJ 1999 CCR5 promoter alleles and specific DNA binding factors. Science 284: 223. *

• Buhler MM, Craig M, Donaghue KC, Badhwar P, Willis J, Manolios N, Tait BD, Silink M, Bennetts BH, Stewart GJ 2002 CCR5 genotyping in an Australian and New Zealand type 1 diabetes cohort. Autoimmunity 35: 457-461.

• Burman A, Haworth O, Hardie DL, Amft EN, Siewert C, Jackson DG, Salmon M, Buckley CD 2005 A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J. Immunol. 174: 1693-1700. *

• Burns JC, Shimizu C, Gonzalez E, Kulkarni H, Patel S, Shike H, Sundel RS, Newburger JW, Ahuja SK 2005 Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J. Infect. Dis. 192: 344-349. *

• Calderwood SK, Mambula SS, Gray PJ Jr, Theriault JR 2007 Extracellular heat shock proteins in cell signaling. FEBS Lett. 581: 3689-3694. *

• Cantor J, Haskins K 2007 Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 diabetes: evidence for involvement of CCR8 and CCL1. J. Immunol. 179: 5760-5767.

• Capelli A, Di Stefano A, Gnemmi I, Donner CF 2005 CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 25: 701-707. *

• Capoulade-Metay C, Ayouba A, Kfutwah A, Lole K, Petres S, Dudoit Y, Deterre P, Menu E, Barre-Sinoussi F, Debre P, Theodorou I 2006 A natural CCL5/RANTES variant antagonist for CCR1 and CCR3. Immunogenetics 58: 533-541. *

• Carrington M, Kissner T, Gerrard B, Ivanov S, O'Brien SJ, Dean M 1997 Novel alleles of the chemokine-receptor gene CCR5. Am. J. Hum. Genet. 61: 1261-1267. *

• Carter CJ 2008 Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, Herpes simplex, Rubella, and Toxoplasma gondii. Schizophr. Bull. Jun 13 [Epub ahead of print].

• Casas R, Lindau C, Zetterstrom O, Duchen K 2008 Downregulation of CXCR6 and CXCR3 in lymphocytes from birch-allergic patients. Scand. J. Immunol. 68: 351-361. *

• Castagna A, Biswas P, Beretta A, Lazzarin A 2005 The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs 65: 879-904.

• Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN 2006 Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440: 890-895. *

• Catano G, Agan BK, Kulkarni H, Telles V, Marconi VC, Dolan MJ, Ahuja SK 2008 Independent effects of genetic variations in mannose-binding lectin influence the course of HIV disease: the advantage of heterozygosity for coding mutations. J. Infect. Dis. 198: 72-80.

• Cavassani KA, Campanelli AP, Moreira AP, Vancim JO, Vitali LH, Mamede RC, Martinez R, Silva JS 2006 Systemic and local characterization of regulatory T cells in a chronic fungal infection in humans. J. Immunol. 177: 5811-5818. *

• Chandra AP, Ouyang L, Yi S, Wong JK, Ha H, Walters SN, Patel AT, Stokes R, Jardine M, Hawthorne WJ, O'Connell PJ 2007 Chemokine and Toll-like receptor signaling in macrophage mediated islet xenograft rejection. Xenotransplantation 14: 48-59. *

• Charnaux N, Brule S, Chaigneau T, Saffar L, Sutton A, Hamon M, Prost C, Lievre N, Vita C, Gattegno L 2005 RANTES (CCL5) induces a CCR5-dependent accelerated shedding of syndecan-1 (CD138) and syndecan-4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD44. Glycobiology 15: 119-130. *

• Civatte M, Bartoli C, Schleinitz N, Chetaille B, Pellissier JF, Figarella-Branger D 2005 Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol. Appl. Neurobiol. 31: 70-79.

• Clark VJ, Dean M 2004 Haplotype structure and linkage disequilibrium in chemokine and chemokine receptor genes. Hum. Genomics 1: 255-273.

• Clark VJ, Dean M 2004 Characterisation of SNP haplotype structure in chemokine and chemokine receptor genes using CEPH pedigrees and statistical estimation. Hum. Genomics 1: 195-207.

• Coban C, Ishii KJ, Uematsu S, Arisue N, Sato S, Yamamoto M, Kawai T, Takeuchi O, Hisaeda H, Horii T, Akira S 2007 Pathological role of Toll-like receptor signaling in cerebral malaria. Int. Immunol. 19: 67-79.

• Cohen J 2004 Medicine. Microbicide shuts the door on HIV. Science 306: 387. *

• Combarros O, Infante J, Llorca J, Pena N, Fernandez-Viadero C, Berciano J 2004 The chemokine receptor CCR5-Delta32 gene mutation is not protective against Alzheimer's disease. Neurosci. Lett. 366: 312-314. *

• Connor SJ, Paraskevopoulos N, Newman R, Cuan N, Hampartzoumian T, Lloyd AR, Grimm MC 2004 CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut 53: 1287-1294. *

• Contento RL, Molon B, Boularan C, Pozzan T, Manes S, Marullo S, Viola A 2008 CXCR4-CCR5: a couple modulating T cell functions. Proc. Natl. Acad. Sci. U.S.A. 105: 10101-10106. *

• Conti L, Cardone M, Varano B, Puddu P, Belardelli F, Gessani S 2008 Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur. J. Immunol. 38: 750-762. *

• Cornwell PD, Ulrich RG 2007 Investigating the mechanistic basis for hepatic toxicity induced by an experimental chemokine receptor 5 (CCR5) antagonist using a compendium of gene expression profiles. Toxicol. Pathol. 35: 576-588. *

• Craggs A, Welfare M, Donaldson PT, Mansfield JC 2001 The CC chemokine receptor 5 delta32 mutation is not associated with inflammatory bowel disease (IBD) in NE England. Genes Immun. 2: 114-116. *

• Cruickshank SM, English NR, Felsburg PJ, Carding SR 2005 Characterization of colonic dendritic cells in normal and colitic mice. World J. Gastroenterol. 11: 6338-6347. *

• de Groot M, Teunissen MB, Ortonne JP, Lambert JR, Naeyaert JM, Picavet DI, Arreaza MG, Simon JS, Kraan M, Bos JD, de Rie MA 2007 Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch. Dermatol. Res. 299: 305-313. *

• de Jong PR, Schadenberg AW, Jansen NJ, Prakken BJ 2008 Hsp70 and cardiac surgery: molecular chaperone and inflammatory regulator with compartmentalized effects. Cell Stress Chaperones Jul 31 [Epub ahead of print].

• de Silva E, Stumpf MP 2004 HIV and the CCR5-Delta32 resistance allele. FEMS Microbiol. Lett. 241: 1-12. *

• Degerli N, Yilmaz E, Bardakci F 2005 The Delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin. Biochem. 38: 248-252. *

• Denkers EY, Butcher BA, Del Rio L, Kim L 2004 Manipulation of mitogen-activated protein kinase/nuclear factor-kappaB-signaling cascades during intracellular Toxoplasma gondii infection. Immunol. Rev. 201: 191-205. *

• Desmetz C, Lin YL, Mettling C, Portales P, Noel D, Clot J, Jorgensen C, Corbeau P 2007 Cell surface CCR5 density determines the intensity of T cell migration towards rheumatoid arthritis synoviocytes. Clin. Immunol. 123: 148-154. *

• Desmetz C, Lin YL, Mettling C, Portales P, Rabesandratana H, Clot J, Corbeau P 2006 The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density. Immunology 119: 551-561. *

• Diedrichs-Mohring M, Nelson PJ, Proudfoot AE, Thurau SR, Wildner G 2005 The effect of the CC chemokine receptor antagonist Met-RANTES on experimental autoimmune uveitis and oral tolerance. J. Neuroimmunol. 164: 22-30.

• Ditzel HJ, Rosenkilde MM, Garred P, Wang M, Koefoed K, Pedersen C, Burton DR, Schwartz TW 1998 The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokineand HIV-1-blocking human antibodies. Proc. Natl. Acad. Sci. U.S.A. 95: 5241-5255. *

• Doms RW 2004 Unwelcome guests with master keys: how HIV enters cells and how it can be stopped. Top. HIV Med. 12: 100-103. *

• Duan RS, Chen Z, Bao L, Quezada HC, Nennesmo I, Winblad B, Zhu J 2004 CCR5 deficiency does not prevent P0 peptide 180-199 immunized mice from experimental autoimmune neuritis. Neurobiol. Dis. 16: 630-637.

• Duncan CJ, Scott S 2005 What caused the Black Death? Postgrad. Med. J. 81: 315-320. *

• Duncan SR, Scott S, Duncan CJ 2005 Reappraisal of the historical selective pressures for the CCR5-Delta32 mutation. J. Med. Genet. 42: 205-208. *

• Dybkaer K, Iqbal J, Zhou G, Geng H, Xiao L, Schmitz A, D' Amore F, Chan WC 2007 Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways. BMC Genomics 8: 230. *

• El-Asmar L, Springael JY, Ballet S, Urizar Andrieu E, Vassart G, Parmentier M 2005 Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol. Pharmacol. 67: 460-469. *

• Eltayeb S, Berg AL, Lassmann H, Wallstrom E, Nilsson M, Olsson T, Ericsson-Dahlstrand A, Sunnemark D 2007 Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. J. Neuroinflammation 4: 14.

• Elvin SJ, Williamson ED, Scott JC, Smith JN, Perez De Lema G, Chilla S, Clapham P, Pfeffer K, Schlondorff D, Luckow B 2004 Evolutionary genetics: ambiguous role of CCR5 in Y. pestis infection. Nature 430: 417.

• Eri R, Jonsson JR, Pandeya N, Purdie DM, Clouston AD, Martin N, Duffy D, Powell EE, Fawcett J, Florin TH, Radford-Smith GL 2004 CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun. 5: 444-450. *

• Favorova OO, Andreewski TV, Boiko AN, Sudomoina MA, Alekseenkov AD, Kulakova OG, Slanova AV, Gusev EI 2002 The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology 59: 1652-1655.

• Favorova OO, Favorov AV, Boiko AN, Andreewski TV, Sudomoina MA, Alekseenkov AD, Kulakova OG, Gusev EI, Parmigiani G, Ochs MF 2006 Three allele combinations associated with multiple sclerosis. BMC Med. Genet. 7: 63. *

• Fischer-Maas L, Schneppenheim R, Oyen F, Grabhorn E, Richter A, Fischer L, Ganschow R 2008 Analysis of the CC chemokine receptor 5Delta32 polymorphism in pediatric liver transplant recipients. Pediatr. Transplant. Jan 8 [Epub ahead of print].

• Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, Uglialoro AM, Clavijo OP, Rosenberg ES, Kalams SA, Braun JD, Boswell SL, Walker BD, Goldfeld AE 2001 Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl. Acad. Sci. U.S.A. 98: 5140-5145. *

• Floto RA, MacAry PA, Boname JM, Mien TS, Kampmann B, Hair JR, Huey OS, Houben EN, Pieters J, Day C, Oehlmann W, Singh M, Smith KG, Lehner PJ 2006 Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 314: 454-458. *

• Folwaczny M, Glas J, Torok HP, Fricke K, Folwaczny C 2003 Prevalence of the chemokine receptor CCR5-Delta32 gene mutation in periodontal disease. Clin. Immunol. 109: 325-329. *

• Freysdottir J, Zhang S, Tilakaratne WM, Fortune F 2007 Oral biopsies from patients with orofacial granulomatosis with histology resembling Crohn's disease have a prominent Th1 environment. Inflamm. Bowel Dis. 13: 439-445. *

• Gade-Andavolu R, Comings DE, MacMurray J, Rostamkhani M, Cheng LS, Tourtellotte WW, Cone LA 2004 Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet. Med. 6: 126-131.

• Galvani AP, Novembre J 2005 The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect. 7: 302-309. *

• Galvani AP, Slatkin M 2003 Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc. Natl. Acad. Sci. U.S.A. 100: 15276-15279. *

• Gambelunghe G, Ghaderi M, Gharizadeh B, Brozzetti A, Tortoioli C, Del Sindaco P, Sanjeevi CB, Hjelmstrom P, Sirsjo A, Nyren P, Santeusanio F, Falorni A 2004 Lack of association of human chemokine receptor gene polymorphisms CCR2-64I and CCR5-Delta32 with autoimmune Addison's disease. Eur. J. Immunogenet. 31: 73-76. *

• Garcia-Vicuna R, Gomez-Gaviro MV, Dominguez-Luis MJ, Pec MK, Gonzalez-Alvaro I, Alvaro-Gracia JM, Diaz-Gonzalez F 2004 CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum. 50: 3866-3877. *

• Garred P, Madsen HO, Petersen J, Marquart H, Hansen TM, Freiesleben Sorensen S, Volck B, Svejgaard A, Andersen V 1998 CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J. Rheumatol. 25: 1462-1465.

• Gharagozloo M, Doroudchi M, Farjadian S, Pezeshki AM, Ghaderi A 2005 The frequency of CCR5Delta32 and CCR2-64I in southern Iranian normal population. Immunol. Lett. 96: 277-281.

• Ghilardi G, Biondi ML, Battaglioli L, Zambon A, Guagnellini E, Scorza R 2004 Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 Delta32 deletion. J. Vasc. Surg. 40: 995-1000.

• Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlondorff D, Plewig G, Sander CA, Rocken M 2003 Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9: 40-46. *

• Giri RK, Rajagopal V, Kalra VK 2004 Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J. Neurochem. 91: 1199-1210. *

• Giscombe R, Wang XB, Kakoulidou M, Lefvert AK 2006 Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis. J. Intern. Med. 260: 224-230. *

• Glas J, Torok HP, Simperl C, Konig A, Martin K, Schmidt F, Schaefer M, Schiemann U, Folwaczny C 2003 The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirin. Clin. Immunol. 108: 46-50. *

• Gomez-Reino JJ, Pablos JL, Carreira PE, Santiago B, Serrano L, Vicario JL, Balsa A, Figueroa M, de Juan MD 1999 Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum. 42: 989-992. *

• Gong X, Feng H, Zhang S, Yu Y, Li J, Wang J, Guo B 2007 Increased expression of CCR5 in experimental autoimmune myocarditis and reduced severity induced by anti-CCR5 monoclonal antibody. J. Mol. Cell. Cardiol. 42: 781-791. *

• Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, Anderson SA, Walter EA, Stephan KT, Hammer MF, Mangano A, Sen L, Clark RA, Ahuja SS, Dolan MJ, Ahuja SK 2001 Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc. Natl. Acad. Sci. U.S.A. 98: 5199-5204. *

• Gonzalez P, Alvarez R, Batalla A, Reguero JR, Alvarez V, Astudillo A, Cubero GI, Cortina A, Coto E 2001 Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2: 191-195. *

• Goyal A, Suneetha PV, Kumar GT, Shukla DK, Arora N, Sarin SK 2006 CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C. World J. Gastroenterol. 12: 4721-4726. *

• Graudal N 2004 The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins. Scand. J. Rheumatol. Suppl. 118: 1-38.

• Grissell TV, Chang AB, Gibson PG 2007 Reduced Toll-like receptor 4 and substance P gene expression is associated with airway bacterial colonization in children. Pediatr. Pulmonol. 42: 380-385.

• Guan Y, Jiang Z, Ciric B, Rostami AM, Zhang GX 2008 Upregulation of chemokine receptor expression by IL-10/IL-4 in adult neural stem cells. Exp. Mol. Pathol. Aug 6 [Epub ahead of print]. *

• Haase CG, Schmidt S, Faustmann PM 2002 Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci. Lett. 330: 293-295. *

• Hall IP, Wheatley A, Christie G, McDougall C, Hubbard R, Helms PJ 1999 Association of CCR5 delta32 with reduced risk of asthma. Lancet 354: 1264-1265. *

• Hampe J, Lynch NJ, Daniels S, Bridger S, Macpherson AJ, Stokkers P, Forbes A, Lennard-Jones JE, Mathew CG, Curran ME, Schreiber S 2001 Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel disease. Gut 48: 191-197. *

• He S, Cao Q, Yoneyama H, Ge H, Zhang Y, Zhang Y 2008 MIP-3alpha and MIP-1alpha rapidly mobilize dendritic cell precursors into the peripheral blood. J. Leukoc. Biol. Sep 12 [Epub ahead of print].

• Hedman M, Faresjo M, Axelsson S, Ludvigsson J, Casas R 2008 Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children. Clin. Exp. Immunol. 153: 360-368.

• Heesen M, Schippers EF, Bloemeke B, Kunz D, van Dissel JT 2003 Cytokine response to endotoxin in individuals heterozygous for the Delta32 mutation of chemokine receptor CCR5. Cytokine 21: 195-199.

• Heggelund L, Damas JK, Yndestad A, Holm AM, Muller F, Lien E, Espevik T, Aukrust P, FrOland SS 2004 Stimulation of Toll-like receptor 2 in mononuclear cells from HIV-infected patients induces chemokine responses: possible pathogenic consequences. Clin. Exp. Immunol. 138: 116-121. *

• Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, Satsangi J, Wright M, Zhang L, Thomas HC, Thursz M, Hill AV 2003 Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38: 1468-1476. *

• Henckaerts L, Fevery J, Van Steenbergen W, Verslype C, Nevens F, Yap P, Roskams T, Rutgeerts P, Vermeire S 2007 The RANTES -28 g polymorphism is associated with primary sclerosing cholangitis. Gut 56: 891-892. *

• Henckaerts L, Fevery J, Van Steenbergen W, Verslype C, Yap P, Nevens F, Roskams T, Libbrecht L, Rutgeerts P, Vermeire S 2006 CC-type chemokine receptor 5-[DELTA]32 mutation protects against primary sclerosing cholangitis. Inflamm. Bowel Dis. 12: 272-277. *

• Henneken M, Dorner T, Burmester GR, Berek C 2005 Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res. Ther. 7: R1001-R1013. *

• Herfarth H, Pollok-Kopp B, Goke M, Press A, Oppermann M 2001 Polymorphism of CC chemokine receptors CCR2 and CCR5 in Crohn's disease. Immunol. Lett. 77: 113-117.

• Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, Catron D, Buchanan ME, Muller A, deWaal Malefyt R, Deng G, Orozco R, Ruzicka T, Lehmann P, Lebecque S, Caux C, Zlotnik A 2000 Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164: 6621-6632. *

• Hosek J, Bartosova L, Gregor P, Kolorz M, Díte P, Batovsky M, Bartos M 2008 Frequency of representative single nucleotide polymorphisms associated with inflammatory bowel disease in the Czech Republic and Slovak Republic. Folia Biol. (Praha.) 54: 88-96.

• Houman H, Hamzaoui A, Ben Ghorbal I, Khanfir M, Feki M, Hamzaoui K 2004 Abnormal expression of chemokine receptors in Behcet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J. Autoimmun. 23: 267-273.

• Hsu TC, Tzang BS, Huang CN, Lee YJ, Liu GY, Chen MC, Tsay GJ 2006 Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells. Clin. Exp. Immunol. 144: 152-157. *

• Hsu W, Rosenquist GL, Ansari AA, Gershwin ME 2005 Autoimmunity and tyrosine sulfation. Autoimmun. Rev. 4: 429-435.

• Hsu YH, Hsieh MS, Liang YC, Li CY, Sheu MT, Chou DT, Chen TF, Chen CH 2004 Production of the chemokine eotaxin-1 in osteoarthritis and its role in cartilage degradation. J. Cell. Biochem. 93: 929-939. *

• Huerta C, Alvarez V, Mata IF, Coto E, Ribacoba R, Martinez C, Blazquez M, Guisasola LM, Salvador C, Lahoz CH, Pena J 2004 Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci. Lett. 370: 151-154.

• Hugues S, Scholer A, Boissonnas A, Nussbaum A, Combadiere C, Amigorena S, Fetler L 2007 Dynamic imaging of chemokine-dependent CD8+ T cell help for CD8+ T cell responses. Nat. Immunol. 8: 921-930. *

• Hummel M, Bara C, Hirt S, Haverich A, Hetzer R 2007 Prevalence of CCR5Delta32 polymorphism in long-term survivors of heart transplantation. Transpl. Immunol. 17: 223-226.

• Hummel S, Schmidt D, Kremeyer B, Herrmann B, Oppermann M 2005 Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons. Genes Immun. 6: 371-374. *

• Ichiyasu H, McCormack JM, McCarthy KM, Dombkowski D, Preffer FI, Schneeberger EE 2004 Matrix metalloproteinase-9-deficient dendritic cells have impaired migration through tracheal epithelial tight junctions. Am. J. Respir. Cell. Mol. Biol. 30: 761-770. *

• Imamura Y, Kurokawa MS, Yoshikawa H, Nara K, Takada E, Masuda C, Tsukikawa S, Ozaki S, Matsuda T, Suzuki N 2005 Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease. Clin. Exp. Immunol. 139: 371-378. *

• Ina Y, Sakai K 2005 Activation of immunological network by chronic low-dose-rate irradiation in wild-type mouse strains: analysis of immune cell populations and surface molecules. Int. J. Radiat. Biol. 81: 721-729.

• Irony-Tur-Sinai M, Grigoriadis N, Lourbopoulos A, Pinto-Maaravi F, Abramsky O, Brenner T 2006 Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. Exp. Neurol. 198: 136-144.

• Jagodzinski PP, Lecybyl R, Ignacak M, Juszczyk J, Trzeciak WH 2000 Distribution of 32 alelle of the CCR5 gene in the population of Poland. J. Hum. Genet. 45: 271-274.

• Jaksch M, Remberger M, Mattsson J 2005 Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 11: 280-287.

• Jang DH, Choi BS, Kim SS 2008 The effects of RANTES/CCR5 promoter polymorphisms on HIV disease progression in HIV-infected Koreans. Int. J. Immunogenet. 35: 101-105. *

• Jayasuriya H, Herath KB, Ondeyka JG, Polishook JD, Bills GF, Dombrowski AW, Springer MS, Siciliano S, Malkowitz L, Sanchez M, Guan Z, Tiwari S, Stevenson DW, Borris RP, Singh SB 2004 Isolation and structure of antagonists of chemokine receptor (CCR5). J. Nat. Prod. 67: 1036-1038. *

• Jia Y, Li H, Chen W, Li M, Lv M, Feng P, Hu H, Zhang L 2006 Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES. Gene Ther. 13: 1351-1359. *

• Jiang XH, Song YL, Long YQ 2004 Facile synthesis of 4-substituted-4-aminopiperidine derivatives, the key building block of piperazine-based CCR5 antagonists. Bioorg. Med. Chem. Lett. 14: 3675-3678. *

• Jin Q, Agrawal L, Meyer L, Tubiana R, Theodorou I, Alkhatib G 2008 CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of the CCR5Delta32 protective effects. J. Virol. 82: 2418-2426. *

• Jo Y, Matsumoto T, Yada S, Fujisawa K, Esaki M, Onai N, Matsushima K, Iida M 2003 CCR4 is an up-regulated chemokine receptor of peripheral blood memory CD4+ T cells in Crohn's disease. Clin. Exp. Immunol. 132: 332-338. *

• Julia E, Montalban X, Al-Zayat H, Issazadeh-Navikas S, Goertsches R, Martin R, Comabella M 2006 Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. J. Neuroimmunol. 180: 147-158.

• Kahmann L, Uciechowski P, Warmuth S, Malavolta M, Mocchegiani E, Rink L 2006 Effect of improved zinc status on T helper cell activation and TH1/TH2 ratio in healthy elderly individuals. Biogerontology 7: 429-435. *

• Kaimen-Maciel DR, Vissoci Reiche EM, Brum Souza DG, Frota Comini ER, Bobroff F, Morimoto HK, Ehara Watanabe MA, Carvalho De Oliveira J, Matsuo T, Lopes J, Donadi EA 2007 CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis. Int. J. Mol. Med. 20: 337-344.

• Kallikourdis M, Andersen KG, Welch KA, Betz AG 2007 Alloantigen-enhanced accumulation of CCR5+ ‘effector’ regulatory T cells in the gravid uterus. Proc. Natl. Acad. Sci. U.S.A. 104: 594-599. *

• Kallinich T, Schmidt S, Hamelmann E, Fischer A, Qin S, Luttmann W, Virchow JC, Kroczek RA 2005 Chemokine-receptor expression on T cells in lung compartments of challenged asthmatic patients. Clin. Exp. Allergy 35: 26-33.

• Kamkamidze G, Capoulade-Metay C, Butsashvili M, Dudoit Y, Chubinishvili O, Debre P, Theodorou I 2005 32-Nucleotide deletion, associated with defence against HIV/AIDS, is a predominant mutation of CCR5 gene in the population of Georgia. Georgian Med. News 1: 74-79.

• Kang SG, Piniecki RJ, Hogenesch H, Lim HW, Wiebke E, Braun SE, Matsumoto S, Kim CH 2007 Identification of a chemokine network that recruits FoxP3(+) regulatory T cells into chronically inflamed intestine. Gastroenterology 132: 966-981. *

• Kantarci OH, Morales Y, Ziemer PA, Hebrink DD, Mahad DJ, Atkinson EJ, Achenbach SJ, De Andrade M, Mack M, Ransohoff RM, Lassmann H, Bruck W, Weinshenker BG, Lucchinetti CF 2005 CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J. Neuroimmunol. 169: 137-143.

• Kantor R, Bakhanashvili M, Achiron A 2003 A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology 61: 238-240.

• Kantor R, Barzilai A, Varon D, Martinowitz U, Gershoni JM 1998 Prevalence of a CCR5 gene 32-bp deletion in an Israeli cohort of HIV-1-infected and uninfected hemophilia patients. J. Hum. Virol. 1: 299-301.

• Kantor R, Gershoni JM 1999 Distribution of the CCR5 gene 32-base pair deletion in Israeli ethnic groups. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20: 81-84.

• Kaur G, Singh P, Rapthap CC, Kumar N, Vajpayee M, Sharma SK, Wanchu A, Mehra NK 2007 Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians. Hum. Immunol. 68: 454-461.

• Kawamura T, Bruce SE, Abraha A, Sugaya M, Hartley O, Offord RE, Arts EJ, Zimmerman PA, Blauvelt A 2004 PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J. Virol. 78: 7602-7609. *

• Khademi B, Razmkhah M, Erfani N, Gharagozloo M, Ghaderi A 2008 SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol. Oncol. Res. 14: 45-50.

• Khaliq S, Hameed A, Ayub Q, Mazhar K, Mohyuddin A, Mansoor A, Mehdi SQ 2002 Frequency of CCR5 gene 32-bp deletion in Pakistani ethnic groups. Genet. Test. 6: 123-127.

• Kim DH, Jung HD, Lee NY, Sohn SK 2007 Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. Transplantation 84: 917-925.

• Kitamura K, Nakamoto Y, Kaneko S, Mukaida N 2004 Pivotal roles of interleukin-6 in transmural inflammation in murine T cell transfer colitis. J. Leukoc. Biol. 76: 1111-1117. *

• Klitz W, Brautbar C, Schito AM, Barcellos LF, Oksenberg JR 2001 Evolution of the CCR5 Delta32 mutation based on haplotype variation in Jewish and Northern European population samples. Hum. Immunol. 62: 530-538.

• Knight JC 2005 Regulatory polymorphisms underlying complex disease traits. J. Mol. Med. 83: 97-109. *

• Ko J, Yun CY, Lee JS, Kim DH, Yuk JE, Kim IS 2006 Differential regulation of CC chemokine receptors by 9-cis retinoic acid in the human mast cell line, HMC-1. Life Sci. 79: 1293-1300. *

• Kohem CL, Brenol JC, Xavier RM, Bredemeier M, Brenol CV, Dedavid TL, Silva E, Mello AD, Canedo AD, Neves AG, Chies JA 2007 The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients. Scand. J. Rheumatol. 36: 359-364.

• Korshunova TIu, Akhmetova VL, Kutuev IA, Khusainova RI, Guseinov GG, Khusnutdinova EK 2004 VNTR-polymorphism of the PAH, e-NOS genes and deletion of the CCR5 gene in populations in the northern Caucasus. Genetika 40: 409-414.

• Kremeyer B, Hummel S, Herrmann B 2005 Frequency analysis of the delta32ccr5 HIV resistance allele in a medieval plague mass grave. Anthropol. Anz. 63: 13-22.

• Kroll-Palhares K, Silverio JC, Silva AA, Michailowsky V, Marino AP, Silva NM, Carvalho CM, Pinto LM, Gazzinelli RT, Lannes-Vieira J 2008 TNF/TNFR1 signaling up-regulates CCR5 expression by CD8+ T lymphocytes and promotes heart tissue damage during Trypanosoma cruzi infection: beneficial effects of TNF-alpha blockade. Mem. Inst. Oswaldo Cruz. 103: 375-385.

• Kudo T, Nagata S, Aoyagi Y, Suzuki R, Matsuda H, Ohtsuka Y, Shimizu T, Okumura K, Yamashiro Y 2004 Polarized production of T-helper cell type 1 cells in Peyer's patches in Crohn's disease. Digestion 70: 214-225.

• Lamprecht P, Bruhl H, Erdmann A, Holl-Ulrich K, Csernok E, Seitzer U, Mack M, Feller AC, Reinhold-Keller E, Gross WL, Muller A 2003 Differences in CCR5 expression on peripheral blood CD4+CD28- T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin. Immunol. 108: 1-7. *

• Lavergne E, Combadiere C, Iga M, Boissonnas A, Bonduelle O, Maho M, Debre P, Combadiere B 2004 Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J. Immunol. 173: 3755-3762. *

• Le Souef PN 2006 Variations in genetic influences on the development of asthma throughout childhood, adolescence and early adult life. Curr. Opin. Allergy Clin. Immunol. 6: 317-322.

• Lederman MM, Sieg SF 2007 CCR5 and its ligands: a new axis of evil? Nat. Immunol. 8: 1283-1285. *

• Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M Jr, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O 2004 Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306: 485-487. *

• Li C, Lu SC, Hsieh PS, Huang YH, Huang HI, Ying TH, Shieh B 2005 Distribution of human chemokine (C-X-C) receptor 1 (CXCR1) gene polymorphisms and haplotypes of the CC chemokine receptor 5 (CCR5) promoter in Chinese people, and the effects of CCR5 haplotypes on CCR5 expression. Int. J. Immunogenet. 32: 99-106.

• Li M, Song R, Masciotra S, Soriano V, Spira TJ, Lal RB, Yang C 2005 Association of CCR5 human haplogroup E with rapid HIV type 1 disease progression. AIDS Res. Hum. Retroviruses 21: 111-115.

• Li S, Gokden N, Okusa MD, Bhatt R, Portilla D 2005 Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am. J. Physiol. Renal Physiol. 289: F469-F480. *

• Libert F, Cochaux P, Beckman G, Samson M, Aksenova M, Cao A, Czeizel A, Claustres M, de la Rua C, Ferrari M, Ferrec C, Glover G, Grinde B, Guran S, Kucinskas V, Lavinha J, Mercier B, Ogur G, Peltonen L, Rosatelli C, Schwartz M, Spitsyn V, Timar L, et al 1998 The Deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum. Mol. Genet. 7: 399-406. *

• Lim HW, Lee J, Hillsamer P, Kim CH 2008 Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J. Immunol. 180: 122-129.

• Lim JK, Glass WG, McDermott DH, Murphy PM 2006 CCR5: no longer a 'good for nothing' gene - chemokine control of West Nile virus infection. Trends Immunol. 27: 308-312. *

• Limborska SA, Balanovsky OP, Balanovskaya EV, Slominsky PA, Schadrina MI, Livshits LA, Kravchenko SA, Pampuha VM, Khusnutdinova EK, Spitsyn VA 2002 Analysis of CCR5Delta32 geographic distribution and its correlation with some climatic and geographic factors. Hum. Hered. 53: 49-54.

• Lindner E, Nordang GB, Melum E, Flato B, Selvaag AM, Thorsby E, Kvien TK, Forre OT, Lie BA 2007 Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis. BMC Med. Genet. 8: 33. *

• Liou JM, Lin JT, Huang SP, Wu CY, Wang HP, Lee YC, Chiu HM, Shun CT, Lin MT, Wu MS 2008 RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women. J. Gastroenterol. 43: 115-123. *

• Liu LY, Jarjour NN, Busse WW, Kelly EA 2003 Chemokine receptor expression on human eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental antigen challenge. J. Allergy Clin. Immunol. 112: 556-562.

• Lobo PI, Schlegel KH, Spencer CE, Okusa MD, Chisholm C, McHedlishvili N, Park A, Christ C, Burtner C 2008 Naturally occurring IgM anti-leukocyte autoantibodies (IgM-ALA) inhibit T cell activation and chemotaxis. J. Immunol. 180: 1780-1791.

• Losana G, Bovolenta C, Rigamonti L, Borghi I, Altare F, Jouanguy E, Forni G, Casanova JL, Sherry B, Mengozzi M, Trinchieri G, Poli G, Gerosa F, Novelli F 2002 IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes. J. Leukoc. Biol. 72: 735-742. *

• Luangsay S, Kasper LH, Rachinel N, Minns LA, Mennechet FJ, Vandewalle A, Buzoni-Gatel D 2003 CCR5 mediates specific migration of Toxoplasma gondii-primed CD8 lymphocytes to inflammatory intestinal epithelial cells. Gastroenterology 125: 491-500. *

• Luckow B, Joergensen J, Chilla S, Li JP, Henger A, Kiss E, Wieczorek G, Roth L, Hartmann N, Hoffmann R, Kretzler M, Nelson PJ, De Lema GP, Maier H, Wurst W, Balling R, Pfeffer K, Grone HJ, Schlondorff D, Zerwes HG 2004 Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5-deficient mice. Eur. J. Immunol. 34: 2568-2578. *

• Lucotte G 2002 Frequencies of 32 base pair deletion of the (Delta 32) allele of the CCR5 HIV-1 co-receptor gene in Caucasians: a comparative analysis. Infect. Genet. Evol. 1: 201-205.

• Lucotte G 2001 Distribution of the CCR5 gene 32-basepair deletion in West Europe. A hypothesis about the possible dispersion of the mutation by the Vikings in historical times. Hum. Immunol. 62: 933-936.

• Lucotte G 1997 Frequencies of the CC chemokine receptor 5 delta 32 allele in various populations of defined racial background. Biomed. Pharmacother. 51: 469-473.

• Lucotte G, Dieterlen F 2003 More about the Viking hypothesis of origin of the delta32 mutation in the CCR5 gene conferring resistance to HIV-1 infection. Infect. Genet. Evol. 3: 293-295.

• Lucotte G, Mercier G 1998 Distribution of the CCR5 gene 32-bp deletion in Europe. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 19: 174-177.

• Lucotte G, Mercier G, Smets P 1999 Elevated frequencies of the mutant allele delta32 at the CCR5 gene in Ashkenazic Jews. AIDS Res. Hum. Retroviruses 15: 1-2. *

• Lucotte G, Smets P 2003 CCR5-Delta32 allele frequencies in Ashkenazi Jews. Genet. Test. 7: 333-337. *

• Luomala M, Lehtimaki T, Huhtala H, Ukkonen M, Koivula T, Hurme M, Elovaara I 2003 Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol. Scand. 108: 396-400.

• Ma LY, Hong KX, Lu XZ, Qin GM, Chen JP, Chen KL, Ruan YH, Xing H, Zhu JH, Shao YM 2005 Single nucleotide polymorphisms of HIV coreceptor CCR5 gene in Chinese Yi ethnic group and its association with HIV infection. Zhonghua Yi Xue Za Zhi 85: 3181-3185.

• Maayan S, Zhang L, Shinar E, Ho J, He T, Manni N, Kostrikis LG, Neumann AU 2000 Evidence for recent selection of the CCR5-delta 32 deletion from differences in its frequency between Ashkenazi and Sephardi Jews. Genes Immun. 1: 358-361. *

• Machado FS, Koyama NS, Carregaro V, Ferreira BR, Milanezi CM, Teixeira MM, Rossi MA, Silva JS 2005 CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J. Infect. Dis. 191: 627-636. *

• Mack M, Cihak J, Simonis C, Luckow B, Proudfoot AE, Plachy J, Bruhl H, Frink M, Anders HJ, Vielhauer V, Pfirstinger J, Stangassinger M, Schlondorff D 2001 Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166: 4697-4704. *

• Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold E, Mitsuya H 2006 Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281: 12688-12698. *

• Maeda K, Nakata H, Ogata H, Koh Y, Miyakawa T, Mitsuya H 2004 The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection. Curr. Opin. Pharmacol. 4: 447-452.

• Maggs JR, Chapman RW 2007 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 23: 310-316.

• Mamtani M, Rovin B, Brey R, Camargo JF, Kulkarni H, Herrera M, Correa P, Holliday S, Anaya JM, Ahuja SK 2008 CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythematosus. Ann. Rheum. Dis. 67: 1076-1083.

• Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, Koblin B, Seage GR 3rd; HIV Network for Prevention Trials Vaccine Preparedness Protocol Team 2001 Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J. Acquir. Immune Defic. Syndr. 27: 472-481.

• Martin A, Gallino N, Gagliardi J, Ortiz S, Lascano AR, Diller A, Daraio MC, Kahn A, Mariani AL, Serra HM 2002 Early inflammatory markers in elicitation of allergic contact dermatitis. BMC Dermatol. 2: 9. *

• Martin K, Heinzlmann M, Borchers R, Mack M, Loeschke K, Folwaczny C 2001 Delta 32 mutation of the chemokine-receptor 5 gene in inflammatory bowel disease. Clin. Immunol. 98: 18-22. *

• Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB 1997 Global distribution of the CCR5 gene 32-basepair deletion. Nat. Genet. 16: 100-103. *

• Mauss S, Puoti M 2006 CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice - clinical implications for CCR5 inhibition as antiretroviral therapy. Hepatology 43: 879. *

• McGinnis R, Child F, Clayton S, Davies S, Lenney W, Illig T, Wjst M, Spurr N, Debouck C, Hajeer AH, Ollier WE, Strange R, Fryer AA 2002 Further support for the association of CCR5 allelic variants with asthma susceptibility. Eur. J. Immunogenet. 29: 525-528. *

• McKinney C, Merriman ME, Chapman PT, Gow PJ, Harrison AA, Highton J, Jones PB, McLean L, O'Donnell JL, Pokorny V, Spellerberg M, Stamp L, Willis J, Steer S, Merriman T 2008 Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis. Ann. Rheum. Dis. 67: 409-413.

• McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, Ernst M, Topley N, Jones SA 2005 IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc. Natl. Acad. Sci. U.S.A. 102: 9589-9594. *

• Meanwell NA, Kadow JF 2007 Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr. Opin. Investig. Drugs 8: 669-681.

• Mecsas J, Franklin G, Kuziel WA, Brubaker RR, Falkow S, Mosier DE 2004 Evolutionary genetics: CCR5 mutation and plague protection. Nature 427: 606. *

• Melum E, Karlsen TH, Broome U, Thorsby E, Schrumpf E, Boberg KM, Lie BA 2006 The 32-base pair deletion of the chemokine receptor 5 gene (CCR5-Delta32) is not associated with primary sclerosing cholangitis in 363 Scandinavian patients. Tissue Antigens 68: 78-81. *

• Mo R, Chen J, Grolleau-Julius A, Murphy HS, Richardson BC, Yung RL 2005 Estrogen regulates CCR gene expression and function in T lymphocytes. J. Immunol. 174: 6023-6029. *

• Moench C, Uhrig A, Lohse AW, Otto G 2004 CC chemokine receptor 5Delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl. 10: 434-439. *

• Mohan K, Issekutz TB 2007 Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J. Immunol. 179: 8463-8469.

• Mokubo A, Tanaka Y, Nakajima K, Watada H, Hirose T, Kawasumi M, Sakai K, Kanazawa A, Maeda S, Hosokawa K, Atsumi Y, Matsuoka K, Kawamori R 2006 Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism (59029A/G) is associated with diabetic nephropathy in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetes Res. Clin. Pract. 73: 89-94.

• Montecucco F, Steffens S, Burger F, Da Costa A, Bianchi G, Bertolotto M, Mach F, Dallegri F, Ottonello L 2008 Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways. Cell. Signal. 20: 557-568. *

• Moreno C, Deviere J, Louis H 2006 Reply to "CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice - clinical implications for CCR5 inhibition as antiretroviral therapy". Hepatology 43: 879-880.

• Moreno C, Gustot T, Nicaise C, Quertinmont E, Nagy N, Parmentier M, Le Moine O, Deviere J, Louis H 2005 CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 42: 854-862. *

• Moreno C, Nicaise C, Gustot T, Quertinmont E, Nagy N, Parmentier M, Louis H, Deviere J 2006 Chemokine receptor CCR5 deficiency exacerbates caerulein-induced acute pancreatitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 291: G1089-G1099. *

• Mueller A, Mahmoud NG, Goedecke MC, McKeating JA, Strange PG 2002 Pharmacological characterization of the chemokine receptor, CCR5. Br. J. Pharmacol. 135: 1033-1043. *

• Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, Dick AD 2005 Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch. Ophthalmol. 123: 634-641. *

• Muxel SM, Borelli SD, Amarante MK, Voltarelli JC, Aoki MN, de Oliveira CE, Ehara Watanabe MA 2008 Association study of CCR5 delta 32 polymorphism among the HLA-DRB1 Caucasian population in Northern Parana, Brazil. J. Clin. Lab. Anal. 22: 229-233.

• Nagata S, McKenzie C, Pender SL, Bajaj-Elliott M, Fairclough PD, Walker-Smith JA, Monteleone G, MacDonald TT 2000 Human Peyer's patch T cells are sensitized to dietary antigen and display a Th cell type 1 cytokine profile. J. Immunol. 165: 5315-5321. *

• Nagy A, Kozma GT, Bojszko A, Krikovszky D, Falus A, Szalai C 2002 No association between asthma or allergy and the CCR5Delta 32 mutation. Arch. Dis. Child. 86: 426. *

• Nakamura M, Jo JI, Tabata Y, Ishikawa O 2008 Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (alopecia areata) in a C3H/HeJ mouse model. Am. J. Pathol. 172: 650-658. *

• Nakayama T, Kato Y, Hieshima K, Nagakubo D, Kunori Y, Fujisawa T, Yoshie O 2004 Liver-expressed chemokine/CC chemokine ligand 16 attracts eosinophils by interacting with histamine H4 receptor. J. Immunol. 173: 2078-2083. *

• Nansen A, Christensen JP, Andreasen SO, Bartholdy C, Christensen JE, Thomsen AR 2002 The role of CC chemokine receptor 5 in antiviral immunity. Blood 99: 1237-1245. *

• Navratilova Z 2006 Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 150: 191-204.

• Nguyen DH, Taub D 2002 CXCR4 function requires membrane cholesterol: implications for HIV infection. J. Immunol. 168: 4121-4126. *

• Nguyen DH, Taub D 2002 Cholesterol is essential for macrophage inflammatory protein 1 beta binding and conformational integrity of CC chemokine receptor 5. Blood 99: 4298-4306. *

• Nguyen DH, Taub DD 2003 Inhibition of chemokine receptor function by membrane cholesterol oxidation. Exp. Cell. Res. 291: 36-45. *

• Nguyen GT, Carrington M, Beeler JA, Dean M, Aledort LM, Blatt PM, Cohen AR, DiMichele D, Eyster ME, Kessler CM, Konkle B, Leissinger C, Luban N, O'Brien SJ, Goedert JJ, O'Brien TR 1999 Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J. Acquir. Immune Defic. Syndr. 22: 75-82.

• Nischalke HD, Nattermann J, Lichterfeld M, Woitas RP, Rockstroh JK, Sauerbruch T, Spengler U 2004 Rapid determination of the Delta32 deletion in the human CC-chemokine receptor 5 (CCR5) gene without DNA extraction by LightCycler real-time polymerase chain reaction. AIDS Res. Hum. Retroviruses 20: 750-754.

• Nissinen R, Leirisalo-Repo M, Nieminen AM, Halme L, Farkkila M, Palosuo T, Vaarala O 2004 Immune activation in the small intestine in patients with rheumatoid arthritis. Ann. Rheum. Dis. 63: 1327-1330. *

• Nold MF, Nold-Petry CA, Pott GB, Zepp JA, Saavedra MT, Kim SH, Dinarello CA 2008 Endogenous IL-32 controls cytokine and HIV-1 production. J. Immunol. 181: 557-565.

• Norii M, Yamamura M, Iwahashi M, Ueno A, Yamana J, Makino H 2006 Selective recruitment of CXCR3(+) and CCR5(+) CCR4(+) T cells into synovial tissue in patients with rheumatoid arthritis. Acta Med. Okayama 60: 149-157.

• Novembre J, Galvani AP, Slatkin M 2005 The geographic spread of the CCR5 Delta32 HIV-resistance allele. PLoS Biol. 3: e339. *

• Nozaki Y, Tamaki C, Yamagata T, Sugiyama M, Ikoma S, Kinoshita K, Funauchi M 2006 All-trans-retinoic acid suppresses interferon-gamma and tumor necrosis factor-alpha; a possible therapeutic agent for rheumatoid arthritis. Rheumatol. Int. 26: 810-817. *

• Oh MD, Kim SS, Kim EY, Lee S, Kim N, Park KY, Kim U, Kim T, Kim T, Choe K, Lee JS 2000 The frequency of mutation in CCR5 gene among Koreans. Int. J. STD AIDS 11: 266-267.

• Ohtani N, Ohtani H, Nakayama T, Naganuma H, Sato E, Imai T, Nagura H, Yoshie O 2004 Infiltration of CD8+ T cells containing RANTES/CCL5+ cytoplasmic granules in actively inflammatory lesions of human chronic gastritis. Lab. Invest. 84: 368-375. *

• Oki M, Ohtani H, Kinouchi Y, Sato E, Nakamura S, Matsumoto T, Nagura H, Yoshie O, Shimosegawa T 2005 Accumulation of CCR5+ T cells around RANTES+ granulomas in Crohn's disease: a pivotal site of Th1-shifted immune response? Lab. Invest. 85: 137-145. *

• Oppenheim JJ, Dong HF, Plotz P, Caspi RR, Dykstra M, Pierce S, Martin R, Carlos C, Finn O, Koul O, Howard OM 2005 Autoantigens act as tissue-specific chemoattractants. J. Leukoc. Biol. 77: 854-861. *

• Oppermann M 2004 Chemokine receptor CCR5: insights into structure, function, and regulation. Cell. Signal. 16: 1201-1210. *

• Otaegui D, Ruiz-Martinez J, Olaskoaga J, Emparanza JI, de Munain AL 2007 Influence of CCR5-Delta32 genotype in Spanish population with multiple sclerosis. Neurogenetics 8: 201-205. *

• Ottaviani C, Nasorri F, Bedini C, de Pita O, Girolomoni G, Cavani A 2006 CD56(bright)CD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur. J. Immunol. 36: 118-128. *

• Ottonello L, Montecucco F, Bertolotto M, Arduino N, Mancini M, Corcione A, Pistoia V, Dallegri F 2005 CCL3 (MIP-1alpha) induces in vitro migration of GM-CSF-primed human neutrophils via CCR5-dependent activation of ERK 1/2. Cell Signal. 17: 355-363. *

• Owen A, Chandler B, Bray PG, Ward SA, Hart CA, Back DJ, Khoo SH 2004 Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J. Virol. 78: 12022-12029. *

• Paavola P, Helio T, Kiuru M, Halme L, Turunen U, Terwilliger J, Karvonen AL, Julkunen R, Niemela S, Nurmi H, Farkkila M, Kontula K 2001 Genetic analysis in Finnish families with inflammatory bowel disease supports linkage to chromosome 3p21. Eur. J. Hum. Genet. 9: 328-334. *

• Panzer U, Schneider A, Steinmetz OM, Wenzel U, Barth P, Reinking R, Becker JU, Harendza S, Zahner G, Fischereder M, Kramer BH, Schlondorff D, Ostendorf T, Floege J, Helmchen U, Stahl RA 2005 The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. Kidney Int. 67: 75-81. *

• Pastinen T, Liitsola K, Niini P, Salminen M, Syvanen AC 1998 Contribution of the CCR5 and MBL genes to susceptibility to HIV type 1 infection in the Finnish population. AIDS Res. Hum. Retroviruses 14: 695-698.

• Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, Mosier DE 2003 Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob. Agents Chemother. 47: 509-517. *

• Pastore C, Ramos A, Mosier DE 2004 Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J. Virol. 78: 7565-7574. *

• Penton-Rol G, Cervantes-Llanos M, Cabrera-Gomez JA, Alonso-Ramirez R, Valenzuela-Silva C, Rodriguez-Lara R, Montero-Casimiro E, Bello-Rivero I, Lopez-Saura P 2008 Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients. Int. Immunopharmacol. 8: 881-886.

• Perney P, Portales P, Clot J, Blanc F, Corbeau P 2004 Diminished CD4+ T cell surface CCR5 expression in alcoholic patients. Alcohol Alcohol. 39: 484-485.

• Petrek M, Cermakova Z, Hutyrova B, Micekova D, Drabek J, Rovensky J, Bosak V 2002 CC chemokine receptor 5 and interleukin-1 receptor antagonist gene polymorphisms in patients with primary Sjogren's syndrome. Clin. Exp. Rheumatol. 20: 701-703.

• Petrek M, Gibejova A, Drabek J, Mrazek F, Kolek V, Weigl E, du Bois RM 2002 CC chemokine receptor 5 (CCR5) mRNA expression in pulmonary sarcoidosis. Immunol. Lett. 80: 189-193.

• Philpott S, Burger H, Charbonneau T, Grimson R, Vermund SH, Visosky A, Nachman S, Kovacs A, Tropper P, Frey H, Weiser B 1999 CCR5 genotype and resistance to vertical transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 21: 189-193.

• Philpott S, Weiser B, Tarwater P, Vermund SH, Kleeberger CA, Gange SJ, Anastos K, Cohen M, Greenblatt RM, Kovacs A, Minkoff H, Young MA, Miotti P, Dupuis M, Chen CH, Burger H 2003 CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. J. Infect. Dis. 187: 569-575. *

• Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV 2006 Interferon-alpha: a key factor in autoimmune disease? Invest. Ophthalmol. Vis. Sci. 47: 3946-3950. *

• Pokorny V, McQueen F, Yeoman S, Merriman M, Merriman T, Harrison A, Highton J, McLean L 2005 Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann. Rheum. Dis. 64: 487-490. *

• Prahalad S 2006 Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun. 7: 264-268. *

• Prahalad S, Bohnsack JF, Jorde LB, Whiting A, Clifford B, Dunn D, Weiss R, Moroldo M, Thompson SD, Glass DN, Bamshad MJ 2006 Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis. Genes Immun. 7: 468-475. *

• Prasad P, Tiwari AK, Prasanna Kumar KM, Ammini AC, Gupta A, Gupta R, Thelma BK 2007 Association of TGFB1, TNFa, CCR2 and CCR5 gene polymorphisms in chronic renal insufficiency among Asian Indians with type-2 diabetes. BMC Med. Genet. 8: 20. *

• Press R, Nennesmo I, Kouwenhoven M, Huang YM, Link H, Pashenkov M 2005 Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J. Neuroimmunol. 159: 165-176.

• Princen K, Hatse S, Vermeire K, Aquaro S, De Clercq E, Gerlach LO, Rosenkilde M, Schwartz TW, Skerlj R, Bridger G, Schols D 2004 Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. J. Virol. 78: 12996-13006. *

• Pulkkinen K, Luomala M, Kuusisto H, Lehtimaki T, Saarela M, Jalonen TO, Elovaara I 2004 Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol. Scand. 109: 342-347.

• Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR 1998 The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101: 746-754. *

• Quinones MP, Ahuja SK, Jimenez F, Schaefer J, Garavito E, Rao A, Chenaux G, Reddick RL, Kuziel WA, Ahuja SS 2004 Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J. Clin. Invest. 113: 856-866. *

• Quinones MP, Estrada CA, Kalkonde Y, Ahuja SK, Kuziel WA, Mack M, Ahuja SS 2005 The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J. Mol. Med. 83: 672-681. *

• Quinones MP, Martinez HG, Jimenez F, Estrada CA, Dudley M, Willmon O, Kulkarni H, Reddick RL, Fernandes G, Kuziel WA, Ahuja SK, Ahuja SS 2007 CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis 195: e92-e103.

• Ramos CD, Canetti C, Souto JT, Silva JS, Hogaboam CM, Ferreira SH, Cunha FQ 2005 MIP-1alpha[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-alpha and LTB4. J. Leukoc. Biol. 78: 167-177. *

• Rasmussen H, Werge T 2007 A closed-tube assay for genotyping of the 32-bp deletion polymorphism in the chemokine receptor 5 (CCR5) gene: dissociation analysis of amplified fragments of DNA. Mol. Cell. Probes 21: 8-11.

• Rasmussen HB, Timm S, Wang AG, Soeby K, Lublin H, Fenger M, Hemmingsen R, Werge T 2006 Association between the CCR5 32-bp deletion allele and late onset of schizophrenia. Am. J. Psychiatry 163: 507-511. *

• Rector A, Vermeire S, Thoelen I, Keyaerts E, Struyf F, Vlietinck R, Rutgeerts P, Van Ranst M 2001 Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum. Genet. 108: 190-193. *

• Ribeiro S, Horuk R 2005 The clinical potential of chemokine receptor antagonists. Pharmacol. Ther. 107: 44-58. *

• Rodriguez-Sosa M, Satoskar AR, Calderon R, Gomez-Garcia L, Saavedra R, Bojalil R, Terrazas LI 2002 Chronic helminth infection induces alternatively activated macrophages expressing high levels of CCR5 with low interleukin-12 production and Th2-biasing ability. Infect. Immun. 70: 3656-3664. *

• Romiti ML, Colognesi C, Cancrini C, Mas A, Berrino M, Salvatori F, Orlandi P, Jansson M, Palomba E, Plebani A, Bertran JM, Hernandez M, de Martino M, Amoroso A, Tovo PA, Rossi P, Espanol T, Scarlatti G 2000 Prognostic value of a CCR5 defective allele in pediatric HIV-1 infection. Mol. Med. 6: 28-36.

• Rucker RP, Day NK, Good RA, Kamchaisatian W, Emmanuel P, Sleasman JW, Mayeski C, Dinglasan E, Haraguchi S, Tangsinmankong N 2004 Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5. Ann. Allergy Asthma Immunol. 93: 272-276.

• Rugeles MT, Solano F, Diaz FJ, Bedoya VI, Patino PJ 2002 Molecular characterization of the CCR 5 gene in seronegative individuals exposed to human immunodeficiency virus (HIV). J. Clin. Virol. 23: 161-169.

• Ruiz-Ferrer M, Barroso N, Antinolo G, Aguilar-Reina J 2004 Analysis of CCR5-Delta32 and CCR2-V64I polymorphisms in a cohort of Spanish HCV patients using Real-time Polymerase Chain Reaction and Fluorescence Resonance Energy Transfer technologies. J. Viral. Hepat. 11: 319-323.

• Salem AH, Batzer MA 2007 Distribution of the HIV resistance CCR5-Delta32 allele among Egyptians and Syrians. Mutat. Res. 616: 175-180.

• Sallusto F, Kremmer E, Palermo B, Hoy A, Ponath P, Qin S, Forster R, Lipp M, Lanzavecchia A 1999 Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur. J. Immunol. 29: 2037-2045. *

• Sandford AJ, Zhu S, Bai TR, Fitzgerald JM, Pare PD 2001 The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J. Allergy Clin. Immunol. 108: 69-73. *

• Santoro F, Vassena L, Lusso P 2004 Chemokine receptors as new molecular targets for antiviral therapy. New Microbiol. 27 (2 Suppl. 1): 17-29.

• Sato W, Aranami T, Yamamura T 2007 Cutting edge: human Th17 cells are identified as bearing CCR2+CCR5- phenotype. J. Immunol. 178: 7525-7529. *

• Scheibel I, Veit T, Neves AG, Souza L, Prezzi S, Machado S, Kohem C, Icarelli M, Xavier R, Brenol JC, Chies JA 2008 Differential CCR5Delta32 allelic frequencies in juvenile idiopathic arthritis subtypes: evidence for different regulatory roles of CCR5 in rheumatological diseases. Scand. J. Rheumatol. 37: 13-17.

• Schroppel B, Fischereder M, Lin M, Marder B, Schiano T, Kramer BK, Murphy B 2002 Analysis of gene polymorphisms in the regulatory region of MCP-1, RANTES, and CCR5 in liver transplant recipients. J. Clin. Immunol. 22: 381-385. *

• Schuh JM, Blease K, Hogaboam CM 2002 The role of CC chemokine receptor 5 (CCR5) and RANTES/CCL5 during chronic fungal asthma in mice. FASEB J. 16: 228-230. *

• Schwabe RF, Bataller R, Brenner DA 2003 Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G949-G958. *

• Sebzda E, Zou Z, Lee JS, Wang T, Kahn ML 2008 Transcription factor KLF2 regulates the migration of naive T cells by restricting chemokine receptor expression patterns. Nat. Immunol. 9: 292-300. *

• Segerer S, Nelson PJ 2005 Chemokines in renal diseases. ScientificWorldJournal 5: 835-844.

• Sellebjerg F, Kristiansen TB, Wittenhagen P, Garred P, Eugen-Olsen J, Frederiksen JL, Sorensen TL 2007 Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol. Scand. 115: 413-418.

• Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P 2000 CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102: 98-106.

• Selmi C, Mackay IR, Gershwin ME 2007 The immunological milieu of the liver. Semin. Liver Dis. 27: 129-139.

• Seneviratne SL, Black AP, Jones L, Bailey AS, Ogg GS 2007 The role of skin-homing T cells in extrinsic atopic dermatitis. QJM 100: 19-27. *

• Shahrara S, Proudfoot AE, Park CC, Volin MV, Haines GK, Woods JM, Aikens CH, Handel TM, Pope RM 2008 Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J. Immunol. 180: 3447-3456.

• Shankaran K, Donnelly KL, Shah SK, Caldwell CG, Chen P, Finke PE, Oates B, MacCoss M, Mills SG, DeMartino JA, Gould SL, Malkowitz L, Siciliano SJ, Springer MS, Kwei G, Carella A, Carver G, Danzeisen R, Hazuda D, Holmes K, Kessler J, Lineberger J, et al 2004 Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists. Bioorg. Med. Chem. Lett. 14: 3589-3593. *

• Shankaran K, Donnelly KL, Shah SK, Guthikonda RN, MacCoss M, Mills SG, Gould SL, Malkowitz L, Siciliano SJ, Springer MS, Carella A, Carver G, Hazuda D, Holmes K, Kessler J, Lineberger J, Miller MD, Emini EA, Schleif WA 2004 Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor. Bioorg. Med. Chem. Lett. 14: 3419-3424. *

• Shao W, Tang J, Song W, Wang C, Li Y, Wilson CM, Kaslow RA 2007 CCL3L1 and CCL4L1: variable gene copy number in adolescents with and without human immunodeficiency virus type 1 (HIV-1) infection. Genes Immun. 8: 224-231. *

• Sharda S, Gilmour A, Harris V, Singh VP, Sinha N, Tewari S, Ramesh V, Agrawal S, Mastana S 2008 Chemokine receptor 5 (CCR5) deletion polymorphism in North Indian patients with coronary artery disease. Int. J. Cardiol. 124: 254-258.

• Shea A, Sarr DA, Jones N, Penning L, Eisen G, Gueye-Ndiaye A, Mboup S, Kanki P, Cao H 2004 CCR5 receptor expression is down-regulated in HIV type 2 infection: implication for viral control and protection. AIDS Res. Hum. Retroviruses 20: 630-635.

• Shen DM, Shu M, Mills SG, Chapman KT, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ, Kwei GY, Carella A, Carver G, Holmes K, Schleif WA, Danzeisen R, Hazuda D, Kessler J, Lineberger J, Miller MD, Emini EA 2004 Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains. Bioorg. Med. Chem. Lett. 14: 935-939. *

• Shen DM, Shu M, Willoughby CA, Shah S, Lynch CL, Hale JJ, Mills SG, Chapman KT, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ, Lyons K, Pivnichny JV, Kwei GY, Carella A, Carver G, Holmes K, Schleif WA, Danzeisen R, Hazuda D, et al 2004 Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds. Bioorg. Med. Chem. Lett. 14: 941-945. *

• Shin JJ, Glickstein LJ, Steere AC 2007 High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis. Arthritis Rheum. 56: 1325-1335. *

• Shu M, Loebach JL, Parker KA, Mills SG, Chapman KT, Shen DM, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ, Salvo JD, Lyons K, Pivnichny JV, Kwei GY, Carella A, Carver G, Holmes K, Schleif WA, Danzeisen R, Hazuda D, Kessler J, et al 2004 Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment. Bioorg. Med. Chem. Lett. 14: 947-952. *

• Sica A, Saccani A, Borsatti A, Power CA, Wells TN, Luini W, Polentarutti N, Sozzani S, Mantovani A 1997 Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J. Exp. Med. 185: 969-974. *

• Sidoti A, D'Angelo R, Rinaldi C, De Luca G, Pino F, Salpietro C, Giunta DE, Saltalamacchia F, Amato A 2005 Distribution of the mutated delta32 allele of the CCR5 gene in a Sicilian population. Int. J. Immunogenet. 32: 193-198.

• Silversides JA, Heggarty SV, McDonnell GV, Hawkins SA, Graham CA 2004 Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult. Scler. 10: 149-152.

• Slatkin M, Bertorelle G 2001 The use of intraallelic variability for testing neutrality and estimating population growth rate. Genetics 158: 865-874. *

• Smoljanovic M, Ristic S, Hayward C 2006 Historic exposure to plague and present-day frequency of CCR5del32 in two isolated island communities of Dalmatia, Croatia. Croat. Med. J. 47: 579-584. *

• Sorensen LN, Paludan SR 2004 Blocking CC chemokine receptor (CCR) 1 and CCR5 during herpes simplex virus type 2 infection in vivo impairs host defence and perturbs the cytokine response. Scand. J. Immunol. 59: 321-333. *

• Srivastava A, Pandey SN, Choudhuri G, Mittal B 2008 CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility. Scand. J. Immunol. 67: 516-522. *

• Stasikowska O, Danilewicz M, Wagrowska-Danilewicz M 2007 The significant role of RANTES and CCR5 in progressive tubulointerstitial lesions in lupus nephropathy. Pol. J. Pathol. 58: 35-40.

• Stenstad H, Ericsson A, Johansson-Lindbom B, Svensson M, Marsal J, Mack M, Picarella D, Soler D, Marquez G, Briskin M, Agace WW 2006 Gut-associated lymphoid tissue-primed CD4+ T cells display CCR9-dependent and -independent homing to the small intestine. Blood 107: 3447-3454. *

• Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M, Winkler C, Huttley GA, Allikmets R, Schriml L, Gerrard B, Malasky M, Ramos MD, Morlot S, Tzetis M, Oddoux C, di Giovine FS, Nasioulas G, Chandler D, Aseev M, Hanson M, et al 1998 Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am. J. Hum. Genet. 62: 1507-1515. *

• Struyf F, Thoelen I, Charlier N, Keyaerts E, Van der Donck I, Wuu J, Van Ranst M 2000 Prevalence of CCR5 and CCR2 HIV-coreceptor gene polymorphisms in Belgium. Hum. Hered. 50: 304-307. *

• Su B, Sun G, Lu D, Xiao J, Hu F, Chakraborty R, Deka R, Jin L 2000 Distribution of three HIV-1 resistance-conferring polymorphisms (SDF1-3'A, CCR2-641, and CCR5-delta32) in global populations. Eur. J. Hum. Genet. 8: 975-979. *

• Sun L, Abdelwahab SF, Lewis GK, Garzino-Demo A 2004 Recall antigen activation induces prompt release of CCR5 ligands from PBMC: implication in memory responses and immunization. Int. Immunol. 16: 1623-1631. *

• Suneetha PV, Sarin SK, Goyal A, Kumar GT, Shukla DK, Hissar S 2006 Association between vitamin D receptor, CCR5, TNF-alpha and TNF-beta gene polymorphisms and HBV infection and severity of liver disease. J. Hepatol. 44: 856-863. *

• Szczucinski A, Losy J 2007 Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol. Scand. 115: 137-146. *

• Takedatsu H, Mitsuyama K, Matsumoto S, Handa K, Suzuki A, Takedatsu H, Funabashi H, Okabe Y, Hara T, Toyonaga A, Sata M 2004 Interleukin-5 participates in the pathogenesis of ileitis in SAMP1/Yit mice. Eur. J. Immunol. 34: 1561-1569. *

• Takeuchi A, Usui Y, Takeuchi M, Hattori T, Kezuka T, Suzuki J, Okunuki Y, Iwasaki T, Haino M, Matsushima K, Usui M 2005 CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response. Invest. Ophthalmol. Vis. Sci. 46: 3753-3760. *

• Tang W, Zhou R, Yang Y, Li YC, Yang YF, Zuo JP 2006 Suppression of (5R)-5-hydroxytriptolide (LLDT-8) on allograft rejection in full MHC-mismatched mouse cardiac transplantation. Transplantation 81: 927-933.

• Tao JH, Li XP, Li XM, Kan M, Zhai ZM, Wang W 2006 Correlation of chemokines and chemokine receptors with clinical features in newly diagnosed systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 86: 3051-3054.

• Terada M, Tsutsui H, Imai Y, Yasuda K, Mizutani H, Yamanishi K, Kubo M, Matsui K, Sano H, Nakanishi K 2006 Contribution of IL-18 to atopic-dermatitis-like skin inflammation induced by Staphylococcus aureus product in mice. Proc. Natl. Acad. Sci. U.S.A. 103: 8816-8821. *

• Terme M, Chaput N, Combadiere B, Ma A, Ohteki T, Zitvogel L 2008 Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J. Immunol. 180: 4679-4686.

• Thimme R, Blum HE 2006 Genetics in viral hepatitis. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 19. *

• Tokuyama H, Ueha S, Kurachi M, Matsushima K, Moriyasu F, Blumberg RS, Kakimi K 2005 The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int. Immunol. 17: 1023-1034.

• Tollenaere C, Rahalison L, Ranjalahy M, Rahelinirina S, Duplantier JM, Brouat C 2008 CCR5 polymorphism and plague resistance in natural populations of the black rat in Madagascar. Infect. Genet. Evol. Jul 25 [Epub ahead of print].

• Tommasi AM, Fabris P, Carderi I, Baragiotta A, Baldo V, Venturi C, Giordani MT, Tositti G, Floreani A 2006 Lack of higher frequency of the chemokine receptor 5-Delta32/Delta32 genotype in hepatitis C. J. Clin. Gastroenterol. 40: 440-443.

• Trebst C, Heiken H, Schmidt RE, Windhagen A, Stangel M 2007 Delta32 polymorphism of the chemokine receptor CCR5 in a patient with multifocal motor neuropathy. Muscle Nerve 35: 541-542.

• Trinh L, Brignole-Baudouin F, Raphael M, Dupont-Monod S, Cassoux N, Lehoang P, Baudouin C 2007 Th1 and Th2 responses on the ocular surface in uveitis identified by CCR4 and CCR5 conjunctival expression. Am. J. Ophthalmol. 144: 580-585.

• Tsimanis A, Kalinkovich A, Bentwich Z 2005 Soluble chemokine CCR5 receptor is present in human plasma. Immunol. Lett. 96: 55-61.

• Turner JE, Steinmetz OM, Stahl RA, Panzer U 2007 Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases. Mini Rev. Med. Chem. 7: 1089-1096.

• Ubogu EE, Callahan MK, Tucky BH, Ransohoff RM 2006 CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro. Cell. Immunol. 243: 19-29. *

• Uchihara JN, Krensky AM, Matsuda T, Kawakami H, Okudaira T, Masuda M, Ohta T, Takasu N, Mori N 2005 Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1. Int. J. Cancer 114: 747-755. *

• Uciechowski P, Kahmann L, Plumakers B, Malavolta M, Mocchegiani E, Dedoussis G, Herbein G, Jajte J, Fulop T, Rink L 2008 TH1 and TH2 cell polarization increases with aging and is modulated by zinc supplementation. Exp. Gerontol. 43: 493-498.

• Uda T, Hifumi E 2004 Super catalytic antibody and antigenase. J. Biosci. Bioeng. 97: 143-152. *

• Ugurel S, Schrama D, Keller G, Schadendorf D, Brocker EB, Houben R, Zapatka M, Fink W, Kaufman HL, Becker JC 2008 Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol. Immunother. 57: 685-691. *

• Vaday GG, Peehl DM, Kadam PA, Lawrence DM 2006 Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66: 124-134.

• Valerio A, Ferrario M, Martinez FO, Locati M, Ghisi V, Bresciani LG, Mantovani A, Spano P 2004 Gene expression profile activated by the chemokine CCL5/RANTES in human neuronal cells. J. Neurosci. Res. 78: 371-382. *

• Vallejo R, De Leon-Casasola O, Benyamin R 2004 Opioid therapy and immunosuppression: a review. Am. J. Ther. 11: 354-365.

• Van Damme J, Struyf S, Opdenakker G 2004 Chemokine-protease interactions in cancer. Semin. Cancer Biol. 14: 201-208. *

• van Veen T, Nielsen J, Berkhof J, Barkhof F, Kamphorst W, Bö L, Ravid R, Verweij CL, Huitinga I, Polman CH, Uitdehaag BM 2007 CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J. Neuroimmunol. 190: 157-164.

• Varani S, Frascaroli G, Homman-Loudiyi M, Feld S, Landini MP, Soderberg-Naucler C 2005 Human cytomegalovirus inhibits the migration of immature dendritic cells by down-regulating cell-surface CCR1 and CCR5. J. Leukoc. Biol. 77: 219-228. *

• Vassiliou EK, Kesler OM, Tadros JH, Ganea D 2008 Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells. J. Immunol. 181: 4534-4544.

• Venkatesan S, Petrovic A, Van Ryk DI, Locati M, Weissman D, Murphy PM 2002 Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration. J. Biol. Chem. 277: 2287-2301. *

• Venzke S, Michel N, Allespach I, Fackler OT, Keppler OT 2006 Expression of Nef downregulates CXCR4, the major coreceptor of human immunodeficiency virus, from the surface of target cells and thereby enhances resistance to superinfection. J. Virol. 80: 11141-11152. *

• Vierboom MP, Zavodny PJ, Chou CC, Tagat JR, Pugliese-Sivo C, Strizki J, Steensma RW, McCombie SW, Celebi-Paul L, Remarque E, Jonker M, Narula SK, Hart B 2005 Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum. 52: 627-636. *

• Vincenti F 2002 What’s in the pipeline? New immunosuppressive drugs in transplantation. Am. J. Transplant. 2: 898-903. *

• Wald O, Pappo O, Ari ZB, Azzaria E, Wiess ID, Gafnovitch I, Wald H, Spengler U, Galun E, Peled A 2004 The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection. Eur. J. Immunogenet. 31: 249-252. *

• Wang M, Windgassen D, Papoutsakis ET 2008 Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation. BMC Genomics 9: 225. *

• Wang X, Staudinger R 2003 Interaction of soluble CD4 with the chemokine receptor CCR5. Biochem. Biophys. Res. Commun. 307: 1066-1069. *

• Wasmuth HE, Werth A, Mueller T, Berg T, Dietrich CG, Geier A, Schirin-Sokhan R, Gartung C, Lorenzen J, Matern S, Lammert F 2004 CC chemokine receptor 5 Delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. J. Mol. Med. 82: 64-69. *

• Wheeler J, McHale M, Jackson V, Penny M 2007 Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. Antivir. Ther. 12: 233-245.

• Whittall T, Wang Y, Younson J, Kelly C, Bergmeier L, Peters B, Singh M, Lehner T 2006 Interaction between the CCR5 chemokine receptors and microbial HSP70. Eur. J. Immunol. 36: 2304-2314. *

• Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Moreno C, Drexhage HA, Versnel MA 2008 Lack of CCR5 on dendritic cells promotes a proinflammatory environment in submandibular glands of the NOD mouse. J. Leukoc. Biol. 83: 1194-1200. *

• Wohlfahrt JC, Wu T, Hodges JS, Hinrichs JE, Michalowicz BS 2006 No association between selected candidate gene polymorphisms and severe chronic periodontitis. J. Periodontol. 77: 426-436.

• Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, Matz B, Offergeld R, Sauerbruch T, Spengler U 2002 Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology 122: 1721-1728. *

• Wong S, Fulcher D 2004 Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk. Lymphoma 45: 2491-2496.

• Wooding S, Stone AC, Dunn DM, Mummidi S, Jorde LB, Weiss RK, Ahuja S, Bamshad MJ 2005 Contrasting effects of natural selection on human and chimpanzee CC chemokine receptor 5. Am. J. Hum. Genet. 76: 291-301. *

• Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, Kirby SL, Luster AD, McKinnon K, Blazar BR, Serody JS 2004 Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J. Immunol. 173: 845-854. *

• Xu Y, Liu H, Niu C, Luo C, Luo X, Shen J, Chen K, Jiang H 2004 Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor. Bioorg. Med. Chem. 12: 6193-6208.

• Yamada S, Oikawa Y, Sakai G, Atsumi Y, Maruyama T, Shimada A 2006 Expression levels of CXC chemokine receptors 3 are associated with clinical phenotype of type 1 diabetes. Ann. N. Y. Acad. Sci. 1079: 186-189. *

• Yanaba K, Mukaida N, Matsushima K, Murphy PM, Takehara K, Sato S 2004 Role of C-C chemokine receptors 1 and 5 and CCL3/macrophage inflammatory protein-1alpha in the cutaneous Arthus reaction: possible attenuation of their inhibitory effects by compensatory chemokine production. Eur. J. Immunol. 34: 3553-3561. *

• Yang B, Houlberg K, Millward A, Demaine A 2004 Polymorphisms of chemokine and chemokine receptor genes in type 1 diabetes mellitus and its complications. Cytokine 26: 114-121.

• Yang L, Liu YF, Wu G, Zhang JL, Wang FS, Fu DZ, Zhao GH, Li TM 2007 Blocking the CC chemokine receptor 5 pathway by antisense peptide nucleic acid prolongs islet allograft survival. Transplant. Proc. 39: 185-190. *

• Yang X, Ahmad T, Gogus F, Wallace GR, Madanat W, Kanawati CA, Stanford MR, Fortune F, Jewell DP, Marshall SE 2004 Analysis of the CC chemokine receptor 5 (CCR5) Delta32 polymorphism in Behcet's disease. Eur. J. Immunogenet. 31: 11-14. *

• Yao ZQ, Prayther D, Trabue C, Dong ZP, Moorman J 2008 Differential regulation of SOCS-1 signalling in B and T lymphocytes by hepatitis C virus core protein. Immunology Apr 4 [Epub ahead of print]. *

• Yarovinsky F, Andersen JF, King LR, Caspar P, Aliberti J, Golding H, Sher A 2004 Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii. J. Biol. Chem. 279: 53635-53642. *

• Yigit B, Bozkurt N, Berber I, Titiz I, Isbir T 2007 Analysis of CC chemokine receptor 5 and 2 polymorphisms and renal transplant survival. Cell. Biochem. Funct. 25: 423-426. *

• Yoon KC, De Paiva CS, Qi H, Chen Z, Farley WJ, Li DQ, Stern ME, Pflugfelder SC 2008 Desiccating environmental stress exacerbates autoimmune lacrimal keratoconjunctivitis in non-obese diabetic mice. J. Autoimmun. 30: 212-221.

• Yopp AC, Fu S, Honig SM, Randolph GJ, Ding Y, Krieger NR, Bromberg JS 2004 FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J. Immunol. 173: 855-865. *

• Yu S, Zhang R, Liu G, Wen W, Shen X 2005 Experiment of genes expression of chemokines and their receptors in allergic rhinitis with gene chip. Lin Chuang Er Bi Yan Hou Ke Za Zhi 19: 52-54.

• Zack Howard OM, Turpin JA, Goldman R, Modi WS 2004 Functional redundancy of the human CCL4 and CCL4L1 chemokine genes. Biochem. Biophys. Res. Commun. 320: 927-931. *

• Zapico I, Coto E, Rodriguez A, Alvarez C, Torre JC, Alvarez V 2000 CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun. 1: 288-289. *

• Zhang M, Ardlie K, Wacholder S, Welch R, Chanock S, O'brien TR 2006 Genetic variations in CC chemokine receptors and hypertension. Am. J. Hypertens. 19: 67-72.

• Zhang M, Schmid S, Carrington M, O'Brien TR 2002 Antibodies to varicella-zoster virus in blood donors with genetic variance in CC chemokine receptor 5. Lancet 359: 1034-1036. *

• Zheng B, Wiklund F, Gharizadeh B, Sadat M, Gambelunghe G, Hallmans G, Dillner J, Wallin KL, Ghaderi M 2006 Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res. 26: 3669-3674.

• Zhou R, Tang W, Ren YX, He PL, Zhang F, Shi LP, Fu YF, Li YC, Ono S, Fujiwara H, Yang YF, Zuo JP 2006 (5R)-5-hydroxytriptolide (LLDT-8) attenuated collagen-induced arthritis in DBA/1 mice via suppressing IFN-gamma production and its related signaling. J. Pharmacol. Exp. Ther. 318: 35-44. *

• Zhou Y, Huang D, Farver C, Hoffman GS 2003 Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener's granulomatosis. J. Rheumatol. 30: 1541-1547.

• Zhu YN, Zhong XG, Feng JQ, Yang YF, Fu YF, Ni J, Liu QF, Tang W, Zhao WM, Zuo JP 2006 Periplocoside E inhibits experimental allergic encephalomyelitis by suppressing IL-12-dependent CCR5 expression and IFN-gamma-dependent CXCR3 expression in T lymphocytes. J. Pharmacol. Exp. Ther. 318: 1153-1162. *

• Zlotnik A 2006 Involvement of chemokine receptors in organ-specific metastasis. Contrib. Microbiol. 13: 191-199.

• Zuniga JA, Villarreal-Garza C, Flores E, Barquera R, Perez-Hernandez N, Montes de Oca JV, Cardiel MH, Vargas-Alarcon G, Granados J 2003 Biological relevance of the polymorphism in the CCR5 gene in refractory and non-refractory rheumatoid arthritis in Mexicans. Clin. Exp. Rheumatol. 21: 351-354.

• Zuo YG, Wang BX, Liu XR, Zhao P, Yan QS 2008 Relationship between CCR5 gene polymorphism and condyloma acuminata. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 30: 95-97.

Number of references = 391

www psc-literature.org